Compare TENX & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TENX | PFX |
|---|---|---|
| Founded | 1967 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.1M | 86.7M |
| IPO Year | 2001 | 2010 |
| Metric | TENX | PFX |
|---|---|---|
| Price | $1.72 | $41.00 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $9.63 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 1.1K |
| Earning Date | 11-11-2026 | 12-11-2026 |
| Dividend Yield | N/A | ★ 3.66% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.30 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $130.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $38.30 |
| 52 Week High | $19.40 | $56.48 |
| Indicator | TENX | PFX |
|---|---|---|
| Relative Strength Index (RSI) | 42.67 | 36.43 |
| Support Level | $1.34 | $38.82 |
| Resistance Level | $2.00 | $42.54 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | 0.09 | -0.40 |
| Stochastic Oscillator | 70.91 | 28.88 |
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.